Adrenocortical carcinoma (ACC) is an aggressive cancer characterized by poor survival.
Apart from radical surgery, there is a limited range of therapeutic options and mitotane …

Careful morphological evaluation forms the basis of the workup of an adrenal cortical
neoplasm. However, the adoption of immunohistochemical biomarkers has added …

Background and aims Previous guidelines addressing surgery of adrenal tumors required
actualization in adaption of developments in the area. The present guideline aims to provide …

Urinary steroid profiling (USP) was studied using high-performance liquid chromatography
(HPLC) and gas chromatography-mass spectrometry (GC-MS) methods in 108 patients with …

Simple Summary The concept of locoregional lymphadenectomy (LND) in adrenocortical
cancer (ACC) has gained interest in recent years, but its definite prognostic and therapeutic …

Mitotane is used as a post-operative adjuvant treatment for patients with adrenocortical
carcinoma. Monitoring of plasma mitotane concentrations is recommended, but we do not …

Adrenocortical carcinoma (ACC) is a malignancy of the endocrine system. We collected
clinical and pathological features, genomic mutations, DNA methylation profiles, and mRNA …

Adrenocortical carcinoma (ACC) is a rare and aggressive tumor with an annual incidence
between 0.7 and 2 cases per million population. ACC is more frequently detected in women …

Adrenocortical carcinoma (ACC) is a heterogeneous malignancy related to poor prognosis
and limited treatment options. The orphan drug mitotane (MT) is still a cornerstone in ACC …

Introduction: Adrenocortical carcinoma (ACC) is a rare tumor characterized by poor
prognosis in most cases. Moreover, in most cases ACC produces an excess of adrenal …